FDA Approves Lantheus' Bravnetsa for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) has formally approved Lantheus Holdings' radioligand therapy drug Bravnetsa (lutetium Lu 177 dotatate injection) for the treatment of somatostatin receptor-positive adult gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approved indication covers neuroendocrine tumors originating from the foregut, midgut, and hindgut.

Following FDA review, Bravnetsa has been determined to be bioequivalent and therapeutically equivalent to the reference drug Lutathera (lutetium Lu 177 dotatate), which is already marketed by Novartis' AAA company (Advanced Accelerator Applications). Bravnetsa was previously developed under the code name PNT2003 and was approved through the FDA's Abbreviated New Drug Application (ANDA) generic drug pathway. Lantheus stated that this drug is the first radioligand therapy approved through the ANDA pathway and is currently the only radiopharmaceutical officially determined by the FDA to be equivalent to Lutathera.

Regarding the mechanism of action, gastroenteropancreatic neuroendocrine tumors primarily occur in the gastrointestinal tract or pancreatic tissue. Lutetium Lu 177 dotatate can specifically bind to somatostatin receptors that are highly expressed on the surface of tumor cells, delivering targeted radiation damage through the targeted release of short-range high-energy β rays. Lantheus, headquartered in Bedford, Massachusetts, has not yet announced a specific commercial launch and delivery date or product pricing at the time of the approval announcement, stating that detailed information regarding supply chain supply and commercial distribution will be released separately.

According to the prescribing information for Bravnetsa, its safety warnings and precautions cover the risk of radiation exposure, myelosuppression, secondary myelodysplastic syndrome and leukemia, nephrotoxicity, hepatotoxicity, hypersensitivity reactions, and neuroendocrine hormonal crisis. The label also indicates embryo-fetal toxicity and potential risk of infertility. The most common Grade 3 or 4 adverse reactions listed in the prescribing information include lymphopenia, elevated γ-glutamyl transferase (GGT), vomiting, nausea, elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT), hyperglycemia, and hypokalemia. Lantheus is currently accelerating the establishment of commercial channels and a radioisotope supply chain network to fully support the subsequent clinical distribution and delivery of this radiopharmaceutical.